Previous close | 1.5400 |
Open | 1.5500 |
Bid | 1.5000 x 100 |
Ask | 1.5800 x 100 |
Day's range | 1.4500 - 1.5900 |
52-week range | 1.3800 - 11.9200 |
Volume | |
Avg. volume | 789,324 |
Market cap | 45.963M |
Beta (5Y monthly) | -0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8700 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.64 |
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Ei
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors harboring RAF or RAS mutations - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering